NewEdge Advisors’s Arbutus Biopharma ABUS Stock Holding History

NewEdge Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-500	Closed	-$2.27K	–	4204
2025 Q3	$2.27K	Hold	500	–	–	﹤0.01%	3754
2025 Q2	$1.54K	Hold	500	–	–	﹤0.01%	3663
2025 Q1	$1.75K	Buy	+500	New	+$1.67K	﹤0.01%	3538
2023 Q3	–	Sell	-10	Closed	-$23	–	3456
2023 Q2	$23	Hold	10	–	–	﹤0.01%	3453
2023 Q1	$30	Hold	10	–	–	﹤0.01%	3377
2022 Q4	$0	Buy	+10	New	+$24	﹤0.01%	4075

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

NewEdge Advisors's ABUS Position: Q4 2025 in Review

NewEdge Advisors sold out of Arbutus Biopharma (ABUS) in Q4 2025, closing a stake of 500 shares — an estimated $2.27K sold.

NewEdge Advisors first reported a position in ABUS in Q4 2022 and held it in 6 quarters. The position peaked at $2.27K in Q3 2025. 172 funds tracked by Wall St. Rank hold ABUS as of Q4 2025.

NewEdge Advisors reported no remaining Arbutus Biopharma position as of Q4 2025 after selling out during the quarter.
NewEdge Advisors sold 500 Arbutus Biopharma shares in Q4 2025, an estimated $2.27K.
NewEdge Advisors first reported a position in Arbutus Biopharma in Q4 2022 and held it in 6 quarters.
NewEdge Advisors's Arbutus Biopharma position peaked at $2.27K in Q3 2025.
172 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.